An open non-comparative pilot study of the safety and efficacy of oral sultamicillin in the treatment of mild to moderate upper respiratory tract infections in children.

Abstract

A total of 49 children (20 females, 29 males; age range, 6 months-12 years) with upper respiratory tract infections (otitis media, sinusitis, pharyngitis and/or tonsillitis) were treated orally with 25 mg/kg.day sultamicillin suspension in two equal doses for an average of 9.2 days. There was bacteriological evidence of sultamicillin-sensitive pathogens in 44 patients prior to treatment. On completion of treatment, 42 (85.7%) patients were rated as clinically cured and there was improvement in the remaining seven (14.2%) patients. Pathogens were totally eradicated in 32/44 (73.7%) cases but were still present in two (4.5%) and in 10 cases follow-up bacteriological evaluation was not possible. Tolerability of sultamicillin was good and only three possible or probable treatment-related adverse events were recorded.

• Authors: A Argüello
• Journal: The Journal of international medical research (J Int Med Res) Vol. 20 Suppl 1 Pg. 24A-30A ( 1992) ISSN: 0300-0605 [Print] England
• PMID: 1451926 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• sultamicillin
• Ampicillin
• Sulbactam

Topics

• Administration, Oral
• Ampicillin (adverse effects, therapeutic use)
• Child
• Child, Preschool
• Drug Therapy, Combination (adverse effects, therapeutic use)
• Female
• Humans
• Infant
• Male
• Moraxella catarrhalis
• Neisseriaceae Infections (drug therapy)
• Pilot Projects
• Respiratory Tract Infections (drug therapy)
• Staphylococcal Infections (drug therapy)
• Sulbactam (adverse effects, therapeutic use)